Literature DB >> 3346676

Evidence that tobacco smoking increases the density of (-)-[3H]nicotine binding sites in human brain.

M E Benwell1, D J Balfour, J M Anderson.   

Abstract

In a postmortem study of nicotinic receptors in human brain, cigarette smoking was found to be associated with increased (-)-[3H]nicotine binding to membranes prepared from gyrus rectus (Brodmann area 11) (p less than 0.001), hippocampal neocortex (Brodmann area 27), cerebellar cortex (p less than 0.01), hippocampal formation (Ammon's horn + subiculum), and the median raphe nuclei of the midbrain (p less than 0.05) but not the medulla oblongata. Analysis of the binding data suggested that the increased binding reflected an increase in the density of the receptors rather than a change in their affinity for (-)-nicotine. The effects of smoking were not influenced significantly by either the sex or age of the subject. It is concluded that smoking evokes an increase in high-affinity nicotine binding similar to that observed previously in animals treated chronically with nicotine and that the effect of smoking on these sites is probably caused by the nicotine present in the tobacco smoke.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3346676     DOI: 10.1111/j.1471-4159.1988.tb10600.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  153 in total

1.  Upregulation of surface alpha4beta2 nicotinic receptors is initiated by receptor desensitization after chronic exposure to nicotine.

Authors:  C P Fenster; T L Whitworth; E B Sheffield; M W Quick; R A Lester
Journal:  J Neurosci       Date:  1999-06-15       Impact factor: 6.167

2.  The regulation of hippocampal nicotinic acetylcholine receptors (nAChRs) after a protracted treatment with selective or nonselective nAChR agonists.

Authors:  J Auta; P Longone; A Guidotti; E Costa
Journal:  J Mol Neurosci       Date:  1999 Aug-Oct       Impact factor: 3.444

3.  Brain metabolic effects of acute nicotine.

Authors:  J W Pettegrew; K Panchalingam; R J McClure; J Levine
Journal:  Neurochem Res       Date:  2001-02       Impact factor: 3.996

4.  Varenicline blocks nicotine intake in rats with extended access to nicotine self-administration.

Authors:  Olivier George; Allison Lloyd; F Ivy Carroll; M Imad Damaj; George F Koob
Journal:  Psychopharmacology (Berl)       Date:  2010-10-06       Impact factor: 4.530

5.  Genetic interaction between alpha4 and beta2 subunits of high affinity nicotinic receptor: analysis in schizophrenia.

Authors:  Vincenzo De Luca; Sophocles Voineskos; Greg Wong; James L Kennedy
Journal:  Exp Brain Res       Date:  2006-04-25       Impact factor: 1.972

6.  Prolonged nicotine dependence associated with extended access to nicotine self-administration in rats.

Authors:  Neil E Paterson; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2004-01-08       Impact factor: 4.530

7.  Nicotinic acetylcholine receptor expression on B-lymphoblasts of healthy versus schizophrenic subjects stratified for smoking: [3H]-nicotine binding is decreased in schizophrenia and correlates with negative symptoms.

Authors:  Christian Luckhaus; Uwe Henning; Stefano Ferrea; Francesco Musso; Arian Mobascher; Georg Winterer
Journal:  J Neural Transm (Vienna)       Date:  2011-12-11       Impact factor: 3.575

8.  Regulation of the distribution and function of [(125)I]epibatidine binding sites by chronic nicotine in mouse embryonic neuronal cultures.

Authors:  Cristian A Zambrano; Rakel M Salamander; Allan C Collins; Sharon R Grady; Michael J Marks
Journal:  J Pharmacol Exp Ther       Date:  2012-04-24       Impact factor: 4.030

9.  Sex differences in availability of β2*-nicotinic acetylcholine receptors in recently abstinent tobacco smokers.

Authors:  Kelly P Cosgrove; Irina Esterlis; Sherry A McKee; Frederic Bois; John P Seibyl; Carolyn M Mazure; Suchitra Krishnan-Sarin; Julie K Staley; Marina R Picciotto; Stephanie S O'Malley
Journal:  Arch Gen Psychiatry       Date:  2012-04

Review 10.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.